These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29165637)

  • 1. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.
    Huang LL; Lee D; Troster SM; Kent AB; Roberts MA; Macdougall IC; McMahon LP
    Nephrol Dial Transplant; 2018 Sep; 33(9):1628-1635. PubMed ID: 29165637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
    Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
    BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
    Roberts MA; Huang L; Lee D; MacGinley R; Troster SM; Kent AB; Bansal SS; Macdougall IC; McMahon LP
    BMC Nephrol; 2016 Nov; 17(1):177. PubMed ID: 27852236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
    Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
    PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.
    Sari V; Atiqi R; Hoorn EJ; Heijboer AC; van Gelder T; Hesselink DA
    Neth J Med; 2017 Mar; 75(2):65-73. PubMed ID: 28276325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
    Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
    BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
    Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose.
    Drakou A; Margeli A; Theodorakopoulou S; Agrogiannis I; Poziopoulos C; Papassotiriou I; Vlahakos DV
    Blood Cells Mol Dis; 2016 Jul; 59():100-5. PubMed ID: 27282576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
    Womack R; Berru F; Panwar B; Gutiérrez OM
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.